Nov. 27, 2006 – In the U.S. smoking remains the biggest cause of death and nearly 70 percent of the people smoking in the nation say that they really want to quit smoking. The astonishing fact remains that the treatments that exist work poorly whereas Chantix has shown superior performance.
Until now estimates figure out that Chantix may account for more than $1 billion of sales in a year and these sales rose up to $33 million while the drug was launched during the days in summer. The results of Chantix are found to be striking because in spite of the fact that it has very little marketing support from the company and other related criticism of the drugs, it was made advertised directly to the consumers until they have been marketed for a period of six months.
Chantix works by deadening cravings for cigarettes and blocking the effects of nicotine on the brain. The FDA approved Chantix in just six months, citing its “significant potential” to improve public health. In clinical tests sponsored by Pfizer, more than 40 percent of Chantix users were smoke-free at 12 weeks, compared with about 30 percent taking Zyban, an antidepressant sold as an aid to smoking cessation. After a year, the smoke-free Chantix users slipped to about 20 percent, not significantly better than Zyban’s results but still twice as good as the results of those taking a placebo.
According to Dr. Rodriguez who has prescribed Chantix to four of its patients prefers it in comparison to Zyban as patients who tried Chantix found it extremely helpful. Unlike the nicotine-replacement, products or anti-anxiety drugs long prescribed for smokers trying to quit, Chantix works by binding to the same receptors in your brain that nicotine does, decreasing cravings for cigarettes.
Please do visit our website http://www.benzer11.com/chantix.html to know more about chantix medicine.
— End —